Infectious Disease Clinical Trial
Official title:
EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN
FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir for 14 days in healthy volunteers. This trial also looks to characterize favipiravir pharmacokinetics in blood and favipiravir levels in sperm. A pharmacogenetics analysis will be conducted in an attempt to identify genetic variants of metabolism and transport enzymes of favipiravir to explain the inter-individual variability of pharmacokinetic parameters of favipiravir. Three sequential dose levels including distinctive participants: - level 1: D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning; - level 2: D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning; - level 3: D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning. Three study groups of maximum of 8 participants, 6 receiving favipiravir and 2 receiving placebo per dose level, three dose levels proposed. Seven additional participants with the same follow up will be included and randomized (6:1 ratio) at the maximum tolerated dose level to allow a satisfactory accurate characterization of pharmacokinetics and pharmacogenetics of favipiravir and their determinants (maximum 39 participants in total, taking into account 8 participants - 2 per dose level - replaced because loss of follow-up before the end of treatment).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
| Completed |
NCT04568889 -
Minnesota COVID-19 Testing Project
|
N/A | |
| Completed |
NCT06063330 -
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
|
Phase 1 | |
| Completed |
NCT01198925 -
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
|
Phase 4 | |
| Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
| Not yet recruiting |
NCT03636711 -
Antibiotic Stewardship in Infectious Disease Departement
|
||
| Completed |
NCT03457688 -
Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children
|
N/A | |
| Completed |
NCT03241355 -
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
|
N/A | |
| Terminated |
NCT05420077 -
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
|
Phase 1 | |
| Completed |
NCT04084106 -
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota
|
Phase 4 | |
| Recruiting |
NCT05013944 -
AnovaOS Network Powered Patient Registry
|
||
| Completed |
NCT03893279 -
Perception of Smell and Taste During Antibiotic Treatment
|
||
| Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
| Completed |
NCT01772901 -
Brief Influenza Vaccine Education to Pregnant Women
|
N/A | |
| Completed |
NCT05413772 -
Temocillin in ESBL-Enterobacteriaceae Infections
|
||
| Completed |
NCT04319328 -
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
|
||
| Completed |
NCT04613271 -
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
|
Phase 3 | |
| Completed |
NCT03239665 -
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
|
N/A | |
| Completed |
NCT03224026 -
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
|
||
| Not yet recruiting |
NCT06102070 -
Genetic Susceptibility to Severe Infections
|